Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03661528 · ClinicalTrials.gov registry record · Phase 4
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
A Phase 4 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 530
- Enrollment target
NCT03661528 is a Phase 4 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 530 participants.
The verdict
NCT03661528, a Phase 4 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 530 participants
- Enrollment target
Study Summary
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant
Interventions
- DRUG Usual Care
- DRUG andexanet alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2023-08-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03661528
The ClinicalTrials.gov registry entry for NCT03661528 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT03661528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03661528 about?
NCT03661528 is a clinical study titled "Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor". Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant
What is the current status of trial NCT03661528?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 530 participants. The study started on 2019-06-06. Estimated completion is 2023-08-09.
What interventions are being tested in trial NCT03661528?
The interventions under investigation include: Usual Care (DRUG), andexanet alfa (DRUG).
Who is sponsoring clinical trial NCT03661528?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.